Considering aesthetic surgery? You need to do your research and become an informed consumer.

Home

Search

Article Archive

Resources / Links

Aesthetic Surgery Books

Skin Care Store

Free Newsletter

INAMED Encouraged by National Cancer Institute Long Term Study of Silicone Gel-Filled Breast Implants  

(press release from Inamed Corporation)

This article sponsored by:

StriVectin-SD Better Than Botox? Anti-Wrinkle, Anti-Aging Breakthrough - On Sale! - Only $99.90!!  - Free Shipping!

SANTA BARBARA, Calif.--Oct. 4, 2004--INAMED Corporation, (NASDAQ:IMDC), is encouraged by results published in the October 1, 2004 issue of the American Journal of Epidemiology. Researchers at the National Cancer Institute (NCI), National Institutes of Health, found no convincing evidence that silicone gel-filled breast implants have an effect on the development of subsequent connective tissue disorders (CTDs).

The researchers used data from one of the largest studies on the long-term health effects of silicone gel-filled breast implants. Scientists at NCI reviewed the medical records of nearly 7,200 women who had cosmetic breast implant surgery before 1989 and were studied in comparison to a cohort of women similar in age who had other types of plastic surgery.

"This study is important and encouraging. The results are consistent with the growing body of published scientific evidence in the United States, and internationally, which is supportive of the long-term safety of silicone gel-filled breast implants," said Nick Teti, Chairman, President and Chief Executive Officer of Inamed Corporation.

The NCI study is one of the most comprehensive retrospective studies to date on the health effects of silicone gel-filled breast implants. The study was conducted in response to a 1992 U.S. Congressional directive to the National Institutes of Health to investigate the long-term safety of these devices. A web-based link to the study is listed below.

http://www.cancer.gov at the NCI home page, type "breast implants"

INAMED Corporation, a global healthcare company with over 25 years of experience developing, manufacturing, and marketing innovative, high-quality, science-based products, including breast implants for aesthetic augmentation and for reconstructive surgery; a range of dermal products for facial rejuvenation; and a minimally invasive device for obesity intervention, the LAP-BAND System.

Forward-Looking Statements

This press release contains forward-looking statements, including, without limitation, express and implied statements regarding INAMED's LAP-BAND(R) System product platform. INAMED is providing this information as of October 04, 2004 and expressly disclaims any duty to update information contained in this press release.

These forward-looking statements involve risks and uncertainties which could cause actual results to differ materially from those expressed or implied here. Readers are referred to the documents filed by INAMED Corporation with the Securities and Exchange Commission, specifically the most recent reports which identify important risk factors that could cause actual results to differ from those contained in the forward-looking statements, including but not limited to: exposure to product liability and intellectual property claims; exposure to liabilities that may not be adequately covered by insurance or for which there is no insurance; potential negative publicity concerning product safety; changes in the economy and consumer spending; competition from existing and/or new products; failure or delay of clinical trials; uncertainty in receiving timely regulatory approval or market acceptance for new products; dependence on a single supplier for INAMED's silicone raw materials; failure to protect INAMED's intellectual property; and adverse changes in the regulatory or legislative environment (both in the U.S. and internationally) affecting our business. The information contained in this press release is a statement of INAMED's present intention, belief or expectation and is based upon, among other things, the existing regulatory environment, industry conditions, market conditions and prices, the economy in general and INAMED's assumptions. INAMED may change its intention, belief or expectation, at any time and without notice, based upon any changes in such factors, in INAMED's assumptions or otherwise. INAMED undertakes no obligation to review or confirm analysts' expectations or estimates or to release publicly any revisions to any forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

By including any information in this press release, INAMED does not necessarily acknowledge that disclosure of such information is required by applicable law or that the information is material.

CONTACTS:

INAMED Corporation
Investors:
Charlie Huiner, Director
Corporate Development & Investor Relations
805-692-5425
or
Media:
Dan Cohen, Vice President
Global Government Affairs
202-638-4179

Knowledge is Power. Information is How You Get It!

PROACTIV SOLUTION ACNE TREATMENT

HYLEXIN

AlphaDerma CE